Metabolon

Metabolon, Inc. is a US-based company specializing in advanced metabolomics services that support biomarker discovery and multiomics research in various sectors such as disease research and drug development. Founded in 2000 in Morrisville, US, Metabolon, Inc. focuses on metabolomics services.

The company has successfully completed 18 deals to date, with its most recent funding round occurring on May 16, 2024. Metabolon raised USD 25. 00 mn in its latest round. The CEO is Rohan Hastie.

Metabolon specializes in advanced metabolomics services that facilitate biomarker discovery and support multiomics research across various fields, including disease research, drug development, and population health. Their core offerings include untargeted metabolomics, targeted metabolomics, lipidomics, and bioinformatics solutions that use ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC/MS/MS). These services enable researchers to identify and quantify a comprehensive range of metabolites, encompassing over 5,400 compounds associated with more than 70 biochemical pathways. Metabolon serves a diverse clientele, including academic institutions, pharmaceutical companies, and healthcare organizations, primarily in North America, Europe, and Asia.

Metabolon generates revenue through direct transactions with clients for its metabolomics services, which often involve a project-based pricing structure. Arrangements may include one-time service contracts, ongoing subscription models for continuous access to data, and partnerships for collaborative research efforts. Their flagship services, such as the Global Discovery Panel and the Microbiome Panel, are designed to cater to specific research needs and facilitate in-depth analysis of biological samples. Pricing plans are tailored based on the type and scope of services required, ensuring that Metabolon meets diverse client needs while maximizing the impact of its metabolomics expertise in advancing scientific research.

In May 2024, Metabolon, Inc. raised USD 42. 50 mn in venture debt funding, part of a larger USD 60 mn round led by new investor Trinity Capital. This funding will be utilized to advance growth programs, boost research and development projects, establish strategic partnerships, retire previous loans, and expand operations worldwide.

The company plans to launch new products focused on enhancing metabolomics capabilities and is targeting expansion in Europe and Asia by 2025.